March 2, 2017 / 12:13 PM / 6 months ago

BRIEF-Sobi says no patients developed inhibitors in Alprolix trial

March 2 (Reuters) - Swedish Orphan Biovitrum (Sobi)

* Says long-term safety and efficacy extension study data of Alprolix for haemophilia B published in thrombosis and haemostasis

* Says the study results reinforce the long-term safety and efficacy of prophylactic treatment with Alprolix over a median duration of more than three years in adults/adolescents and more than a year and a half in children under 12 years of age.

* Says the primary outcome measure was that no patients treated with Alprolix in the study developed inhibitors Source text for Eikon: Further company coverage: (Stockholm Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below